ab bioscience 产品代理
ab bioscience 产品代理
AB Biosciences（ABB）成立于2007年，一直致力于治疗性生物制剂的工程和蛋白质试剂的研究。凭借数十年的研发经验，ABB的科学家已经为这两类蛋白质的开发搭建了一个高效的平台。重组替代传统IVIG（PRIM计划）是我们在研发一种独特蛋白质药物以替代传统血清衍生IVIG方面的工程专业知识的一个很好的例子。
Z-MAB® Next Generation Control Antibody
Checkpoint Proteins
TNFSuperfamily Proteins (Hexa-Ligands)
TNF Receptor Superfamily Proteins
Fc Receptors
ABB’s core competence is in protein designs of biologics for diagnostic and therapeutic applications of immuno-oncological disorders. Specifically, our R&D for therapeutics is focused on biologics that are capable of modulating activities associated with antigenic targets and effector molecules. In addition, ABB has designed and produced a panel of immune related protein reagents that are available to biomedical researchers as investigational tools.
Founded in 2007, AB Biosciences (ABB) has been dedicated to the engineering of therapeutic biologics and research protein reagents. With decades of combined experience in research and development, ABB’s scientists have built an efficient platform for the development of these two protein classes. The recombinant replacement of the traditional IVIG (PRIM program) is a great example of our engineering expertise in R&D of an unique protein drug for replacing the traditional serum-derived IVIG.
